8-K current report · filed Apr 15, 2026

Tango Therapeutics, Inc. (TNGX) 8-K Current Report: April 15, 2026

Item 5.02Item 7.01Item EX-99.1TNGX overview

Short answer

Tango Therapeutics, Inc. (TNGX) filed an 8-K current report with the SEC on April 15, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). CFO Daniella Beckman departing effective April 15, 2026, creating near-term finance leadership transition risk.

Tango Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • CFO Daniella Beckman departing effective April 15, 2026, creating near-term finance leadership transition risk
  • Matthew Gall appointed CFO and principal financial officer, bringing prior CFO experience at Kalaris Therapeutics and iTeos Therapeutics
  • Gall compensation: $540,000 base salary plus 40% target cash bonus opportunity
  • Equity package includes 240,000 stock options and 40,000 restricted stock units, subject to continued employment
  • Jessica Newcomb appointed principal accounting officer, providing internal accounting continuity as finance leadership changes

Item 7.01 · Regulation FD Disclosure

  • Exhibit 99.1 furnished under Regulation FD, rather than filed under Section 18 of the Exchange Act
  • Exhibit 99.1 excluded from automatic incorporation by reference in other Securities Act or Exchange Act filings

Item EX-99.1 · Exhibit EX-99.1

  • Matthew Gall appointed CFO effective April 15, succeeding Daniella Beckman
  • Yen-Ching Chua appointed Chief Development Operations Officer effective June 1
  • Janice Kapty appointed SVP, Corporate Strategy and Project Leadership effective April 15
  • Leadership expansion targets late-stage development and potential commercialization of vopimetostat
  • Initial combination-trial data with Revolution Medicines’ RAS(ON) inhibitors expected in 2026

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tango Therapeutics, Inc. 8-K filings

Get the next TNGX 8-K as it lands

Follow TNGX for push alerts, or ask the research agent what this filing means.